Kyprolis® Meets Primary Endpoint of PFS in Head-to-Head Clinical Trial

The myeloma drug Kyprolis® (carfilzomib) has met the primary endpoint of progression-free survival (PFS) when compared with Velcade® (bortezomib) in patients with relapsed myeloma, according to Amgen/Onyx's recent ENDEAVOR clinical trial interim analysis. Data from this kind of “head-to-head” clinical trial comparing different myeloma treatments “help considerably… to determine the best new treatment paradigm,” IMF Chairman Dr. Brian Durie writes in his blog this week
Source: International Myeloma Foundation - Category: Hematology Source Type: news